The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Today’s studies explore adding nimotuzumab to chemotherapy to treat KRAS wild-type pancreatic cancer and adding ibrutinib to standard care for older adults with mantle cell lymphoma.
In this podcast, Dr. Christopher Flowers discusses research from the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, including studies evaluating new treatments for diffuse large B-cell lymphoma and an overview of a session on improving equity in cancer clinical trials.
Read research from the January 2022 session of the ASCO Plenary Series, which highlights a study comparing 2 targeted therapies in treating advanced gastrointestinal stromal tumors (GISTs).
Stage IV lung cancer survivor Frank Sierawski shares what it was like being diagnosed with cancer at age 35 and how he learned to cope with the diagnosis by living in the moment.
In this podcast, 4 experts discuss the first-ever targeted therapies approved for people with non-small cell lung cancer with an epidermal growth factor receptor (EGFR) exon 20 insertion mutation, including how they work and what they mean for people with this type of cancer.
Research from the first ASCO Plenary Series presentation has arrived. Read more about studies on using immunotherapy to treat metastatic melanoma and how technology can be used to find and manage symptoms during cancer treatment.
In this podcast, Cancer.Net Associate Editors discuss new research presented at the 2021 ASCO Annual Meeting on brain tumors, esophageal cancer, and colorectal cancer.
In this podcast, Cancer.Net Associate Editors discuss new research presented at the 2021 ASCO Annual Meeting in lung cancer, breast cancer, and sarcoma and describe what this research means for people with cancer.
ASCO’s 2021 Advance of the Year highlights how progress in the treatment of gastrointestinal (GI) cancers is driven by molecular testing of tumors.
Dr. Neeraj Agarwal discusses 3 clinical trials presented at the 2020 ESMO Virtual Congress that studied new treatments for advanced kidney cancer, prostate cancer, and bladder cancer.
